This proposal represents a request for continued funding of the NIH-sponsored Clinical Pharmacology T32 Fellowship Training Program at the Mayo Clinic. The foundation for this program is strong training in state-of-the-art biomedical research as applied to human-drug interactions. The Mayo Clinical Pharmacology training experience includes a curriculum that systematically exposes Trainees to critical aspects of the science that underlies Clinical Pharmacology. However, beyond the formal curriculum, at the heart of the training is an outstanding individual research experience within a supportive mentoring environment. Clinical Pharmacology is a ?bridge discipline? devoted to studies of the interaction between drugs and biological systems. However, within the context of the ongoing ?revolution? that is occurring in biomedical science, a revolution that promises to transform medical practice, Clinical Pharmacology lies at the confluence of molecular pharmacology, genomics and other ?omics? disciplines. In addition, increasingly, bioinformatics, systems pharmacology and novel computational methods are also becoming critical compotents of Clinical Pharmacology?with an ultimate goal of truly ?individualized? and rational drug therapy. Specifically, Clinical Pharmacology seeks to enhance our understanding of the molecular basis for drug response and the application of that information at the translational interface to make it possible to tailor drug therapy to both the underlying disease process and the unique characteristics of each individual patient. Our ability to take advantage of the opportunity represented by the dramatic advances that are occurring in biomedical science to achieve that ?ultimate goal? will require that we train a new generation of Clinical Pharmacologists in ?Systems Clinical Pharmacology?. Large, comprehensive, integrated academic medical centers like the Mayo Clinic are ideally positioned to train this new generation of Clinical Pharmacologists. Mayo is able to do that because of its long history of supporting and performing outstanding basic and clinical medical research and of integrating the two. Mayo also has a long tradition of contining contributions to the discipline of Clinical Pharmacology as well as decades of experience in successfully recruiting and training both physician scientists and laboratory-based translational scientists in Clinical Pharmacology. During the next funding cycle, the Mayo Clinical Pharmacology Fellowship Training Program will continue to emphasize strong laboratory-based research training in a supportive mentored environment joined with a strong and evolving curriuculum and systematic exposure to novel developments in clinical science, with an emphasis on the rapidly advancing nature of biomedical science?all directed toward the goal of preparing each Fellow enrolled in the Program to become a future leader in Clinical Pharmacology.

Public Health Relevance

This proposal is a request for continued NIH funding of the Clinical Pharmacology T32 Fellowship Training Program at the Mayo Clinic. Clinical Pharmacology is the science that encompasses all aspects of the use of drugs or biological therapeutic agents to treat human disease. The rapid pace of the evolution of modern biomedical science has created unique opportunities to develop new and powerful drugs to treat disease, but in order to take advantage of those opportunities, we must train the next generation of Clinical Pharmacologists so they can assist and accelerate these advances?exactly the goal of the Clinical Pharmacology Fellowship Training Program at the Mayo Clinic.

National Institute of Health (NIH)
National Institute of General Medical Sciences (NIGMS)
Institutional National Research Service Award (T32)
Project #
Application #
Study Section
Special Emphasis Panel (ZGM1)
Program Officer
Garcia, Martha
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Mayo Clinic, Rochester
United States
Zip Code
Ahmed, Ahmed T; Weinshilboum, Richard; Frye, Mark A (2018) Benefits of and Barriers to Pharmacogenomics-Guided Treatment for Major Depressive Disorder. Clin Pharmacol Ther 103:767-769
Cairns, Junmei; Fridley, Brooke L; Jenkins, Gregory D et al. (2018) Differential roles of ERRFI1 in EGFR and AKT pathway regulation affect cancer proliferation. EMBO Rep 19:
Kohorst, Mira A; Warad, Deepti M; Nageswara Rao, Amulya A et al. (2018) Obesity, sedentary lifestyle, and video games: The new thrombophilia cocktail in adolescents. Pediatr Blood Cancer 65:e27041
Ahmed, Ahmed T; Frye, Mark A; Rush, A John et al. (2018) Mapping depression rating scale phenotypes onto research domain criteria (RDoC) to inform biological research in mood disorders. J Affect Disord 238:1-7
Yan, Yiyi; Kumar, Anagha Bangalore; Finnes, Heidi et al. (2018) Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy. Front Immunol 9:1739
Yu, Jia; Qin, Bo; Moyer, Ann M et al. (2018) DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Invest 128:2376-2388
Norris, Robin E; Fox, Elizabeth; Reid, Joel M et al. (2018) Phase 1 trial of ontuxizumab (MORAb-004) in children with relapsed or refractory solid tumors: A report from the Children's Oncology Group Phase 1 Pilot Consortium (ADVL1213). Pediatr Blood Cancer 65:e26944
Eugene, Andy R (2017) CYP2B6 Genotype Guided Dosing of Propofol Anesthesia in the Elderly based on Nonparametric Population Pharmacokinetic Modeling and Simulations. Int J Clin Pharmacol Toxicol 6:242-249
Eugene, Andy R; Masiak, Jolanta (2017) A pharmacodynamic modelling and simulation study identifying gender differences of daily olanzapine dose and dopamine D2-receptor occupancy. Nord J Psychiatry 71:417-424
Elraiyah, T; Jerde, C R; Shrestha, S et al. (2017) Novel Deleterious Dihydropyrimidine Dehydrogenase Variants May Contribute to 5-Fluorouracil Sensitivity in an East African Population. Clin Pharmacol Ther 101:382-390

Showing the most recent 10 out of 61 publications